Astellas Pharma Inc: Invasive Fungal Infections trials
The registry lists 10 Invasive Fungal Infections studies with Astellas Pharma Inc as lead sponsor. 0 are open to participants now and 2 have results posted.
Phase 1 1Phase 2 1Phase 3 4No phase 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare FungiCompletedNCT00634049Phase 3Results posted
- Isavuconazole (BAL8557) for Primary Treatment of Invasive AspergillosisCompletedNCT00412893Phase 3Results posted
- A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric PatientsCompletedNCT03241550Phase 1
- Non-interventional Study for Prevention and Treatment of Fungal Infections in Paediatric Patients in Asia/Oceania - ERADICATE StudyCompletedNCT03174457
- Registry of Patients Treated With Systemic Mold-Active TriazolesCompletedNCT03066011
- A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal InfectionsCompletedNCT02678598
- Use of Micafungin (Mycamine®) as Antifungal Prophylaxis in Haematology and Onco-haematologyCompletedNCT02127788
- A Study to Evaluate Pre-emptive Treatment for Invasive Candidiasis in High Risk Surgical SubjectsCompletedNCT01122368Phase 2
- Liver Transplant European Study Into the Prevention of Fungal InfectionCompletedNCT01058174Phase 3
- Comparative Study of Micafungin (FK463) Versus Placebo as Prophylactic Antifungal Therapy in the ICUTerminatedNCT00048750Phase 3